体外受精拮抗剂方案种植窗期AIF-1介导的TNF-α表达升高
研究比较GnRH拮抗剂与激动剂长方案IVF周期的子宫内膜AIF-1及TNF-α表达,发现拮抗剂组AIF-1和TNF-α表达更高,AIF-1过表达可抑制JAR细胞黏附,可能不利于胚胎种植。
要点
- GnRH拮抗剂方案周期中AIF-1表达较对照和激动剂组升高。
- AIF-1可介导子宫内膜细胞TNF-α表达增加。
- AIF-1过表达抑制JAR细胞与Ishikawa细胞的黏附。
核心结论
- 拮抗剂方案IVF周期中AIF-1升高并介导种植窗期TNF-α表达增加,可能不利于胚胎种植。
研究设计与样本
- 研究纳入2012至2014年间238例首次接受IVF/ICSI的患者分析种植率和妊娠率。
- 其中40例未行新鲜胚胎移植者分为拮抗剂方案组和激动剂长方案组各20例,另20例输卵管因素不孕未治疗者为对照。
- 同期取18例输卵管因素不孕女性子宫内膜,按早增生期、晚增生期、中分泌期各6例。
- 采用微阵列分析、RT-qPCR、Western blot、免疫组化检测AIF-1及相关细胞因子。
- 用JAR细胞与Ishikawa细胞共培养的体外黏附实验模拟AIF-1对子宫容受性的影响。
主要发现
- AIF-1在早增生期表达最高,晚增生期下降,中分泌期几乎消失。
- 微阵列显示拮抗剂组AIF-1较对照组上调倍数FC=3.75,较激动剂组FC=2.20。
- AIF-1和TNF-α的mRNA及蛋白水平在拮抗剂组均高于其他两组(P < 0.05),其他两组间无显著差异(P > 0.05)。
- 转染AIF-1表达载体96小时后,Ishikawa细胞和原代子宫内膜细胞TNF-α蛋白水平显著增加(P < 0.05)。
- Ishikawa细胞过表达AIF-1抑制JAR细胞对其的黏附。
临床怎么用
- 作者认为抗TNF-α治疗可能减轻GnRH拮抗剂对子宫内膜容受性的不良影响并提高拮抗剂方案IVF的种植率。
局限性
- 微阵列样本量小,可能削弱结果准确性。
- RT-qPCR和Western blotting样本量足以弥补微阵列样本量小的不足。
- AIF-1及TNF-α表达异常只是限制种植成功的众多因素之一。
- 需要进一步广泛的体外机制研究和体内动物研究评估该通路的实际功能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is allograft inflammatory factor-1 (AIF-1), a cytokine associated with inflammation and allograft rejection, aberrantly elevated in in vitro fertilization (IVF) cycles with gonadotropin-releasing hormone (GnRH) antagonist protocol with potential effects on endometrial receptivity? SUMMARY ANSWER: Our findings indicated AIF-1 is increased in IVF cycles with GnRH antagonist protocol and mediates greater TNF-α expression during implantation phase, which may be unfavorable for embryo implantation. WHAT IS KNOWN ALREADY: Studies have shown that GnRH antagonist protocol cycles have lower implantation and clinical pregnancy rates than GnRH agonist long protocol cycles. Endometrial receptivity but not embryo quality is a key factor contributing to this phenomenon; however, the mechanism is still unknown. STUDY DESIGN, SIZE, DURATION: Implantation and pregnancy rates were studied in 238 patients undergoing their first cycle of IVF/ICSI between 2012 and 2014. Forty of these patients opted to have no fresh embryo replacement and were divided into two equal groups: (i) GnRH antagonist protocol and (ii) GnRH agonist long protocol, group 3 included 20 infertile women with a tubal factor in untreated cycles. During the same interval, endometrial tissues were taken from 18 infertile women with a tubal factor in the early proliferative phase, late proliferative phase, and mid-secretory phase of the menstrual cycle (n = 6/group). PARTICIPANTS/MATERIALS, SETTING, METHODS: Microarray analysis, RT-qPCR, Western blot analysis, immunohistochemistry were used to investigate the expression levels of AIF-1 and the related cytokines (TNF-α, IL1β, IL1RA, IL6, IL12, IL15 and IL18). The effect of AIF-1 on uterine receptivity was modeled using in vitro adhesion experiments (coculture of JAR cells and Ishikawa cells). MAIN RESULTS AND THE ROLE OF CHANCE: The expression of AIF-1 was the highest in early proliferative phase, decreasing thereafter in the late proliferative phase, and almost disappearing in the mid-secretory phase, indicating that low AIF-1 expression might be important for embryo implantation during implantation phase. Microarray results revealed that AIF-1 was upregulated in the antagonist group compared with the control group (fold change [FC] = 3.75) and the agonist (FC = 2.20) group. The raw microarray data and complete gene expression table were uploaded to GEO under the accession number of GSE107914. Both the mRNA and protein expression levels of AIF-1 and TNF-α were the higher in the antagonist group than in the other two groups (P < 0.05) which did not differ significantly (P > 0.05). The protein levels of TNF-α in both Ishikawa cells and primary endometrial cells were significantly increased (P < 0.05) at 96 h after transfection with the AIF-1 expression vector, indicating that TNF-α was mediated by AIF-1 in endometrial cells. Overexpression of AIF-1 in Ishikawa cells inhibited adhesion of JAR cells to them. Thus, increased AIF-1 might inhibit adhesion during implantation via raised TNF-α. LIMITATIONS REASONS FOR CAUTION: The sample size of the microarray was small, which might weaken the accuracy of our results; however, the sample size of RT-qPCR and the Western blotting assays were sufficient to compensate for this deficiency in our study. In addition, the aberrant AIF-1 and thus TNF-α expression is one of many factors that may contribute to limiting implantation success. Therefore, further extensive in vitro mechanistic and in vivo animal studies are needed to assess the actual functional impact of this pathway. WIDER IMPLICATIONS OF THE FINDINGS: Anti-TNF-α therapy might mitigate the adverse effects of GnRH antagonist on endometrial receptivity and improve the implantation rate in GnRH antagonist protocols in IVF. STUDY FUNDING/COMPETING INTERESTS: This work was supported by grants from the National Natural Science Foundation of China, Grant numbers 81771656 and 81370763; Clinical research special fund of Chinese Medical Association, Grant number 16020480664; Shanghai Jiao Tong University Medicine-Engineering Fund, Grant number YG2017ZD11 and YG2017MS57; and the Merck-Serono China Research Fund for Fertility Agreement. P.C.K.L. is supported by a Canadian Institutes of Health Research Foundation Scheme Grant 143317. None of the authors has any competing interests.
引用
- Xu B, Zhou M, Wang J, et al. Increased AIF-1-mediated TNF-α expression during implantation phase in IVF cycles with GnRH antagonist protocol. Hum Reprod. 2018. PMID: 29897458. doi:10.1093/humrep/dey119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。